H.C. Wainwright set a price target of $11 for CervoMed (CRVO) shares while keeping a Neutral rating on the name. The regulatory outlook for neflamapimod should be clarified in the near-term, the analyst tells investors in a research note. The firm says CervoMed is actively preparing for discussions with the FDA, which management expects to take place during Q4.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRVO:
- CervoMed price target raised to $31 from $15 at D. Boral Capital
- CervoMed’s Promising Developments and Financial Stability Drive Buy Rating with $20 Price Target
- CervoMed price target lowered to $16 from $20 at Roth Capital
- CervoMed Reports Promising Trial Results and Financial Update
- CervoMed reports Q2 EPS (70c), consensus (50c)